PetMed's market price has been hit hard by declining revenue. Revenue fell from $227 million in FY2025 to $179 million in FY2026. The stock trades as if survival is in question.
Now the question is how PetMeds can become profitable again. During the recent earnings call, management announced that they saved about $6.1 million a year. That is not enough. Material additional savings exist if management aggressively right-sizes the business.
Management has already taken steps to improve efficiency and reduce costs. The company has reorganized its pharmacy, call center, and distribution operations. Headcount was reduced, and existing underperforming vendor relationships ended. Furthermore, they implemented a new ERP system, a new call center platform, and a fraud-prevention system. Together, it's expected to generate approximately $6.1 million in annualized cost savings.
Let’s examine the remaining opportunities for meaningful cost savings.
PetMeds currently employs approximately 189 people while generating $179 million in annual revenue. The company has also experienced significant executive turnover. Currently operating with an interim CEO and interim CFO. PetMeds still has opportunities to streamline its corporate structure. Human resources, finance, legal, compliance, and marketing could all gain efficiency. Estimated annual savings are $1 million to $3 million. The saving thesis is reasonable, but not directly supported by company disclosures.
Marketing Efficiency
Management has stated that it is shifting marketing spending. Advertising expenses totaled approximately $5.8 million in the fourth quarter. And roughly $23 million annually. Even a modest 10% reduction in advertising costs could save more than $2 million a year.
Eliminate Low Margin Categories
Management disclosed a failed wholesale initiative. The $2.1 million inventory write-off indicates expanding into low margin items. Potential candidates include low-margin foods, bulky products, and slow-moving inventory. A focused SKU program could reduce inventory levels and lower working capital requirements. EBIT improvement is possible in the estimated range of $0.5 million to $2 million. This is hard to prove quantitatively because the evidence for the savings is indirect.
Procurement and Supplier Rebates
According to the 10-K, 88% of PetMeds' inventory purchases come from ten suppliers. This level of supplier concentration provides meaningful negotiating leverage. Potential opportunities include securing better supplier rebates, improved payment terms, and volume discounts. Even modest improvements in procurement costs could have a significant impact on profitability. The estimated annual savings are $1 million to $3 million; the estimate is speculative.
PetMeds is a NASDAQ-listed company with a market capitalization of $35 million. Expenses include audits, SEC compliance, legal fees, board compensation, and investor relations. Management has also highlighted elevated professional fees during the past year. If PetMeds were acquired by an outside party. Many of these costs could be eliminated immediately. Estimated annual savings are $2 million to $4 million. It's for the reasons a strategic buyer might pay a premium.
Can PETS Reach a Positive EBITDA?
Based on FY2026 results, PetMeds reported revenue of $179 million and a net loss of $57.3 million. Adjusted EBITDA in the fourth quarter was approximately negative $2.8 million. Annualizing suggests the business is currently operating at roughly negative $10 million to negative $12 million of EBITDA.
So, additional cost reductions of $6 million to $10 million could potentially move the company into a positive EBITDA of $2 million to $8 million.
If revenue stays around current levels and management executes the announced and additional cost-saving measures. PetMeds could generate positive EBITDA of $5 million to $12 million without returning to the $227 million revenue level it reached a year ago.
Conclusion
The $6.1 million savings number has hard evidence from management. THE OTHER SAVINGS ESTIMATES ARE ASSUMPTIONS, NOT COMPANY GUIDANCE!